S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NYSE:AMRX

Amneal Pharmaceuticals (AMRX) Stock Forecast, Price & News

$2.56
+0.01 (+0.39%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.48
$2.58
50-Day Range
$1.36
$2.57
52-Week Range
$1.24
$3.71
Volume
394,499 shs
Average Volume
1.01 million shs
Market Capitalization
$781.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.60

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
83.6% Upside
$4.70 Price Target
Short Interest
Healthy
4.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
20.00%
From $0.40 to $0.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

44th out of 986 stocks

Pharmaceutical Preparations Industry

15th out of 477 stocks


AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Amneal Pharmaceuticals (NYSE:AMRX) Shares Down 2.2%
Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 2.2%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Amneal Pharmaceuticals (AMRX) Gets a Buy from Goldman Sachs
Q1 2023 Amneal Pharmaceuticals Inc Earnings Call
See More Headlines

AMRX Price History

AMRX Company Calendar

Last Earnings
5/05/2023
Today
6/05/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.60
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+40.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
-10.90%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.43 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
223,653,000
Market Cap
$781.95 million
Optionable
Optionable
Beta
1.32

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. PatelChirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Anastasios G. Konidaris
    Executive VP, Chief Financial & Accounting Officer
  • Nikita ShahNikita Shah
    Chief Human Resources Officer & Executive VP
  • Andrew S. Boyer
    Chief Commercial Officer-Generics & Executive VP













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 1-year price targets for Amneal Pharmaceuticals' shares. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they predict the company's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 on January 1st, 2023. Since then, AMRX shares have increased by 28.6% and is now trading at $2.56.
View the best growth stocks for 2023 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a decrease in short interest in April. As of April 30th, there was short interest totaling 6,220,000 shares, a decrease of 9.9% from the April 15th total of 6,900,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.3% of the shares of the stock are short sold.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our AMRX earnings forecast
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings data on Friday, May, 5th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. The firm had revenue of $557.54 million for the quarter, compared to analyst estimates of $555 million. Amneal Pharmaceuticals had a negative net margin of 5.93% and a positive trailing twelve-month return on equity of 107.13%. During the same period in the prior year, the business earned $0.10 EPS.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, April, 21st. The company provided EPS guidance of $0.40-$0.50 for the period, compared to the consensus EPS estimate of $0.50. The company issued revenue guidance of $2.25 billion-$2.35 billion, compared to the consensus revenue estimate of $2.31 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.38%), AQR Capital Management LLC (0.99%), State Street Corp (0.70%), Allspring Global Investments Holdings LLC (0.63%), Geode Capital Management LLC (0.62%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $2.56.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $781.95 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,600 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -